An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. (Q48230747)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Hye-Ryun Kang

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

7

Curie Ahn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

4

Kook-Hwan Oh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

5

Kwon-Wook Joo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Jae-Woo Jung

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Dong-Ki Kim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Yon-Su Kim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Kyung Wha Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sang-Heon Cho

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Kyung-Up Min

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

English

0 references

publication date

29 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

807-814

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/gim.2014.195

29 February 2020

exact match

0 references

cites work

Severe adverse cutaneous reactions to drugs

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Recurrence and mortality following severe cutaneous adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Rapid desensitization for hypersensitivity reactions to chemotherapy agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

A simple salting out procedure for extracting DNA from human nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Allele assignment for HLA-A, -B, and -C genes to the Tenth International Histocompatibility Workshop cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Efficacy and safety of desensitization to allopurinol following cutaneous reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Causal or casual? The role of causality assessment in pharmacovigilance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Adverse drug reactions: definitions, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Epidemiology of hypersensitivity drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2014.195

21 January 2018

Gout and hyperuricemia

1 reference

12 December 2020

Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis

1 reference

12 December 2020

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol

1 reference

12 December 2020

The allopurinol hypersensitivity syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1038/GIM.2014.195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634024%20AND%20SRC:MED&resulttype=core&format=json